BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Euronext Paris 03:43:06 2024-07-17 am EDT | ||
| 5.34 EUR | -8.40% |
|
| Current month | +11.26% | ||
| 1 month | +22.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 5.34 | -8.40% |
| 24-07-16 | 5.83 | -1.02% |
| 24-07-15 | 5.89 | +2.79% |
| 24-07-12 | 5.73 | +5.52% |
| 24-07-11 | 5.43 | -6.22% |
Real-time Euronext Paris
Last update July 17, 2024 at 03:43 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| 7A85S | |
| ISIN | DE000SU78300 |
| Date issued | 2024-02-13 |
| Strike | 635.9 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 2.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.13 € |
|---|---|
| Lowest since issue | 1.86 € |
| Spread | 0.04 € |
| Spread % | 0.74% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
893.8
USD
Spread / Average Target
-5.08%
- Stock Market
- Certificates
- 7A85S Certificat
